Nanomedicine Targeting Myeloid‐Derived Suppressor Cells Enhances Anti‐Tumor Immunity
Cancer immunotherapy, a field within immunology that aims to enhance the host's anti‐cancer immune response, frequently encounters challenges associated with suboptimal response rates. The presence of myeloid‐derived suppressor cells (MDSCs), crucial constituents of the tumor microenvironment (...
Gespeichert in:
| Veröffentlicht in: | Advanced healthcare materials 2024-04, Vol.13 (9), p.e2303294-n/a |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 9 |
| container_start_page | e2303294 |
| container_title | Advanced healthcare materials |
| container_volume | 13 |
| creator | Yang, En‐Li Sun, Zhi‐Jun |
| description | Cancer immunotherapy, a field within immunology that aims to enhance the host's anti‐cancer immune response, frequently encounters challenges associated with suboptimal response rates. The presence of myeloid‐derived suppressor cells (MDSCs), crucial constituents of the tumor microenvironment (TME), exacerbates this issue by fostering immunosuppression and impeding T cell differentiation and maturation. Consequently, targeting MDSCs has emerged as crucial for immunotherapy aimed at enhancing anti‐tumor responses. The development of nanomedicines specifically designed to target MDSCs aims to improve the effectiveness of immunotherapy by transforming immunosuppressive tumors into ones more responsive to immune intervention. This review provides a detailed overview of MDSCs in the TME and current strategies targeting these cells. Also the benefits of nanoparticle‐assisted drug delivery systems, including design flexibility, efficient drug loading, and protection against enzymatic degradation, are highlighted. It summarizes advances in nanomedicine targeting MDSCs, covering enhanced treatment efficacy, safety, and modulation of the TME, laying the groundwork for more potent cancer immunotherapy.
Cancer immunotherapy aims to boost anti‐cancer immune responses but faces hurdles due to myeloid‐derived suppressor cells (MDSCs) in the tumor microenvironment (TME) that hinder T cell activity. Targeting MDSCs with nanomedicines can turn immunosuppressive tumors responsive to immunotherapy. This review delves into MDSCs roles and nanomedicine‐based strategies for MDSCs targeting, setting the stage for future potent cancer immunotherapy. |
| doi_str_mv | 10.1002/adhm.202303294 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2920187288</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2920187288</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3734-90f0e33b3285d1b8530605a673be0333028b3287b7f3f8799b10d4a8317126a03</originalsourceid><addsrcrecordid>eNqFkD1PwzAQhi0EohV0ZUSRWFhSznYSO2PV8iXxMVAkNstJnNZV4gS7AXXjJ_Ab-SW4aikSC17O0j336u5B6ATDEAOQC1nM6yEBQoGSNNpDfYJTEpIkTvd3_wh6aODcAvxLYpxwfIh6lBPOeRL10cuDNE2tCp1ro4KptDO11GYW3K9U1eji6-Nzoqx-U0Xw1LWtVc41NhirqnLBpZlLkysXjMxSe3Da1b53W9ed0cvVMTooZeXUYFuP0PPV5XR8E949Xt-OR3dhThmNwhRKUJRmlPC4wBmPKSQQy4TRTAGlFAhf91jGSlpylqYZhiKSnGKGSSKBHqHzTW5rm9dOuaWotcv9gtKopnOCpAQwZ_5ej579QRdNZ43fTqwNcoYZRJ4abqjcNs5ZVYrW6lralcAg1trFWrvYafcDp9vYLvMmd_iPZA-kG-BdV2r1T5wYTW7uf8O_AYz0jlk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3032871704</pqid></control><display><type>article</type><title>Nanomedicine Targeting Myeloid‐Derived Suppressor Cells Enhances Anti‐Tumor Immunity</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Yang, En‐Li ; Sun, Zhi‐Jun</creator><creatorcontrib>Yang, En‐Li ; Sun, Zhi‐Jun</creatorcontrib><description>Cancer immunotherapy, a field within immunology that aims to enhance the host's anti‐cancer immune response, frequently encounters challenges associated with suboptimal response rates. The presence of myeloid‐derived suppressor cells (MDSCs), crucial constituents of the tumor microenvironment (TME), exacerbates this issue by fostering immunosuppression and impeding T cell differentiation and maturation. Consequently, targeting MDSCs has emerged as crucial for immunotherapy aimed at enhancing anti‐tumor responses. The development of nanomedicines specifically designed to target MDSCs aims to improve the effectiveness of immunotherapy by transforming immunosuppressive tumors into ones more responsive to immune intervention. This review provides a detailed overview of MDSCs in the TME and current strategies targeting these cells. Also the benefits of nanoparticle‐assisted drug delivery systems, including design flexibility, efficient drug loading, and protection against enzymatic degradation, are highlighted. It summarizes advances in nanomedicine targeting MDSCs, covering enhanced treatment efficacy, safety, and modulation of the TME, laying the groundwork for more potent cancer immunotherapy.
Cancer immunotherapy aims to boost anti‐cancer immune responses but faces hurdles due to myeloid‐derived suppressor cells (MDSCs) in the tumor microenvironment (TME) that hinder T cell activity. Targeting MDSCs with nanomedicines can turn immunosuppressive tumors responsive to immunotherapy. This review delves into MDSCs roles and nanomedicine‐based strategies for MDSCs targeting, setting the stage for future potent cancer immunotherapy.</description><identifier>ISSN: 2192-2640</identifier><identifier>ISSN: 2192-2659</identifier><identifier>EISSN: 2192-2659</identifier><identifier>DOI: 10.1002/adhm.202303294</identifier><identifier>PMID: 38288864</identifier><language>eng</language><publisher>Germany: Wiley Subscription Services, Inc</publisher><subject>Cancer ; Cancer immunotherapy ; Cell differentiation ; Differentiation (biology) ; Drug delivery ; Drug delivery systems ; Drug development ; Humans ; Immune system ; Immunology ; Immunosuppression ; Immunotherapy ; Lymphocyte Activation ; Lymphocytes ; Lymphocytes T ; Myeloid-Derived Suppressor Cells - metabolism ; myeloid‐derived suppressor cells ; Nanomedicine ; nanomedicines ; Nanoparticles ; Nanotechnology ; Neoplasms - pathology ; Suppressor cells ; targeted therapy ; Tumor Microenvironment ; Tumors</subject><ispartof>Advanced healthcare materials, 2024-04, Vol.13 (9), p.e2303294-n/a</ispartof><rights>2024 Wiley‐VCH GmbH</rights><rights>2024 Wiley‐VCH GmbH.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3734-90f0e33b3285d1b8530605a673be0333028b3287b7f3f8799b10d4a8317126a03</citedby><cites>FETCH-LOGICAL-c3734-90f0e33b3285d1b8530605a673be0333028b3287b7f3f8799b10d4a8317126a03</cites><orcidid>0000-0003-0932-8013</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fadhm.202303294$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fadhm.202303294$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38288864$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yang, En‐Li</creatorcontrib><creatorcontrib>Sun, Zhi‐Jun</creatorcontrib><title>Nanomedicine Targeting Myeloid‐Derived Suppressor Cells Enhances Anti‐Tumor Immunity</title><title>Advanced healthcare materials</title><addtitle>Adv Healthc Mater</addtitle><description>Cancer immunotherapy, a field within immunology that aims to enhance the host's anti‐cancer immune response, frequently encounters challenges associated with suboptimal response rates. The presence of myeloid‐derived suppressor cells (MDSCs), crucial constituents of the tumor microenvironment (TME), exacerbates this issue by fostering immunosuppression and impeding T cell differentiation and maturation. Consequently, targeting MDSCs has emerged as crucial for immunotherapy aimed at enhancing anti‐tumor responses. The development of nanomedicines specifically designed to target MDSCs aims to improve the effectiveness of immunotherapy by transforming immunosuppressive tumors into ones more responsive to immune intervention. This review provides a detailed overview of MDSCs in the TME and current strategies targeting these cells. Also the benefits of nanoparticle‐assisted drug delivery systems, including design flexibility, efficient drug loading, and protection against enzymatic degradation, are highlighted. It summarizes advances in nanomedicine targeting MDSCs, covering enhanced treatment efficacy, safety, and modulation of the TME, laying the groundwork for more potent cancer immunotherapy.
Cancer immunotherapy aims to boost anti‐cancer immune responses but faces hurdles due to myeloid‐derived suppressor cells (MDSCs) in the tumor microenvironment (TME) that hinder T cell activity. Targeting MDSCs with nanomedicines can turn immunosuppressive tumors responsive to immunotherapy. This review delves into MDSCs roles and nanomedicine‐based strategies for MDSCs targeting, setting the stage for future potent cancer immunotherapy.</description><subject>Cancer</subject><subject>Cancer immunotherapy</subject><subject>Cell differentiation</subject><subject>Differentiation (biology)</subject><subject>Drug delivery</subject><subject>Drug delivery systems</subject><subject>Drug development</subject><subject>Humans</subject><subject>Immune system</subject><subject>Immunology</subject><subject>Immunosuppression</subject><subject>Immunotherapy</subject><subject>Lymphocyte Activation</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Myeloid-Derived Suppressor Cells - metabolism</subject><subject>myeloid‐derived suppressor cells</subject><subject>Nanomedicine</subject><subject>nanomedicines</subject><subject>Nanoparticles</subject><subject>Nanotechnology</subject><subject>Neoplasms - pathology</subject><subject>Suppressor cells</subject><subject>targeted therapy</subject><subject>Tumor Microenvironment</subject><subject>Tumors</subject><issn>2192-2640</issn><issn>2192-2659</issn><issn>2192-2659</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkD1PwzAQhi0EohV0ZUSRWFhSznYSO2PV8iXxMVAkNstJnNZV4gS7AXXjJ_Ab-SW4aikSC17O0j336u5B6ATDEAOQC1nM6yEBQoGSNNpDfYJTEpIkTvd3_wh6aODcAvxLYpxwfIh6lBPOeRL10cuDNE2tCp1ro4KptDO11GYW3K9U1eji6-Nzoqx-U0Xw1LWtVc41NhirqnLBpZlLkysXjMxSe3Da1b53W9ed0cvVMTooZeXUYFuP0PPV5XR8E949Xt-OR3dhThmNwhRKUJRmlPC4wBmPKSQQy4TRTAGlFAhf91jGSlpylqYZhiKSnGKGSSKBHqHzTW5rm9dOuaWotcv9gtKopnOCpAQwZ_5ej579QRdNZ43fTqwNcoYZRJ4abqjcNs5ZVYrW6lralcAg1trFWrvYafcDp9vYLvMmd_iPZA-kG-BdV2r1T5wYTW7uf8O_AYz0jlk</recordid><startdate>20240401</startdate><enddate>20240401</enddate><creator>Yang, En‐Li</creator><creator>Sun, Zhi‐Jun</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QF</scope><scope>7QP</scope><scope>7QQ</scope><scope>7SC</scope><scope>7SE</scope><scope>7SP</scope><scope>7SR</scope><scope>7T5</scope><scope>7TA</scope><scope>7TB</scope><scope>7TM</scope><scope>7TO</scope><scope>7U5</scope><scope>8BQ</scope><scope>8FD</scope><scope>F28</scope><scope>FR3</scope><scope>H8D</scope><scope>H8G</scope><scope>H94</scope><scope>JG9</scope><scope>JQ2</scope><scope>K9.</scope><scope>KR7</scope><scope>L7M</scope><scope>L~C</scope><scope>L~D</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0932-8013</orcidid></search><sort><creationdate>20240401</creationdate><title>Nanomedicine Targeting Myeloid‐Derived Suppressor Cells Enhances Anti‐Tumor Immunity</title><author>Yang, En‐Li ; Sun, Zhi‐Jun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3734-90f0e33b3285d1b8530605a673be0333028b3287b7f3f8799b10d4a8317126a03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Cancer</topic><topic>Cancer immunotherapy</topic><topic>Cell differentiation</topic><topic>Differentiation (biology)</topic><topic>Drug delivery</topic><topic>Drug delivery systems</topic><topic>Drug development</topic><topic>Humans</topic><topic>Immune system</topic><topic>Immunology</topic><topic>Immunosuppression</topic><topic>Immunotherapy</topic><topic>Lymphocyte Activation</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Myeloid-Derived Suppressor Cells - metabolism</topic><topic>myeloid‐derived suppressor cells</topic><topic>Nanomedicine</topic><topic>nanomedicines</topic><topic>Nanoparticles</topic><topic>Nanotechnology</topic><topic>Neoplasms - pathology</topic><topic>Suppressor cells</topic><topic>targeted therapy</topic><topic>Tumor Microenvironment</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, En‐Li</creatorcontrib><creatorcontrib>Sun, Zhi‐Jun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Aluminium Industry Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Ceramic Abstracts</collection><collection>Computer and Information Systems Abstracts</collection><collection>Corrosion Abstracts</collection><collection>Electronics & Communications Abstracts</collection><collection>Engineered Materials Abstracts</collection><collection>Immunology Abstracts</collection><collection>Materials Business File</collection><collection>Mechanical & Transportation Engineering Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>METADEX</collection><collection>Technology Research Database</collection><collection>ANTE: Abstracts in New Technology & Engineering</collection><collection>Engineering Research Database</collection><collection>Aerospace Database</collection><collection>Copper Technical Reference Library</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Materials Research Database</collection><collection>ProQuest Computer Science Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Civil Engineering Abstracts</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>Computer and Information Systems Abstracts Academic</collection><collection>Computer and Information Systems Abstracts Professional</collection><collection>MEDLINE - Academic</collection><jtitle>Advanced healthcare materials</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, En‐Li</au><au>Sun, Zhi‐Jun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nanomedicine Targeting Myeloid‐Derived Suppressor Cells Enhances Anti‐Tumor Immunity</atitle><jtitle>Advanced healthcare materials</jtitle><addtitle>Adv Healthc Mater</addtitle><date>2024-04-01</date><risdate>2024</risdate><volume>13</volume><issue>9</issue><spage>e2303294</spage><epage>n/a</epage><pages>e2303294-n/a</pages><issn>2192-2640</issn><issn>2192-2659</issn><eissn>2192-2659</eissn><abstract>Cancer immunotherapy, a field within immunology that aims to enhance the host's anti‐cancer immune response, frequently encounters challenges associated with suboptimal response rates. The presence of myeloid‐derived suppressor cells (MDSCs), crucial constituents of the tumor microenvironment (TME), exacerbates this issue by fostering immunosuppression and impeding T cell differentiation and maturation. Consequently, targeting MDSCs has emerged as crucial for immunotherapy aimed at enhancing anti‐tumor responses. The development of nanomedicines specifically designed to target MDSCs aims to improve the effectiveness of immunotherapy by transforming immunosuppressive tumors into ones more responsive to immune intervention. This review provides a detailed overview of MDSCs in the TME and current strategies targeting these cells. Also the benefits of nanoparticle‐assisted drug delivery systems, including design flexibility, efficient drug loading, and protection against enzymatic degradation, are highlighted. It summarizes advances in nanomedicine targeting MDSCs, covering enhanced treatment efficacy, safety, and modulation of the TME, laying the groundwork for more potent cancer immunotherapy.
Cancer immunotherapy aims to boost anti‐cancer immune responses but faces hurdles due to myeloid‐derived suppressor cells (MDSCs) in the tumor microenvironment (TME) that hinder T cell activity. Targeting MDSCs with nanomedicines can turn immunosuppressive tumors responsive to immunotherapy. This review delves into MDSCs roles and nanomedicine‐based strategies for MDSCs targeting, setting the stage for future potent cancer immunotherapy.</abstract><cop>Germany</cop><pub>Wiley Subscription Services, Inc</pub><pmid>38288864</pmid><doi>10.1002/adhm.202303294</doi><tpages>27</tpages><orcidid>https://orcid.org/0000-0003-0932-8013</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2192-2640 |
| ispartof | Advanced healthcare materials, 2024-04, Vol.13 (9), p.e2303294-n/a |
| issn | 2192-2640 2192-2659 2192-2659 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2920187288 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Cancer Cancer immunotherapy Cell differentiation Differentiation (biology) Drug delivery Drug delivery systems Drug development Humans Immune system Immunology Immunosuppression Immunotherapy Lymphocyte Activation Lymphocytes Lymphocytes T Myeloid-Derived Suppressor Cells - metabolism myeloid‐derived suppressor cells Nanomedicine nanomedicines Nanoparticles Nanotechnology Neoplasms - pathology Suppressor cells targeted therapy Tumor Microenvironment Tumors |
| title | Nanomedicine Targeting Myeloid‐Derived Suppressor Cells Enhances Anti‐Tumor Immunity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T00%3A45%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nanomedicine%20Targeting%20Myeloid%E2%80%90Derived%20Suppressor%20Cells%20Enhances%20Anti%E2%80%90Tumor%20Immunity&rft.jtitle=Advanced%20healthcare%20materials&rft.au=Yang,%20En%E2%80%90Li&rft.date=2024-04-01&rft.volume=13&rft.issue=9&rft.spage=e2303294&rft.epage=n/a&rft.pages=e2303294-n/a&rft.issn=2192-2640&rft.eissn=2192-2659&rft_id=info:doi/10.1002/adhm.202303294&rft_dat=%3Cproquest_cross%3E2920187288%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3032871704&rft_id=info:pmid/38288864&rfr_iscdi=true |